GSK, Pfizer And Shionogi-owned ViiV Healthcare Will Make At Least 2M Doses Of Long-Acting Cabotegravir For HIV Pre-exposure Prophylaxis Available For Procurement For Low- And Middle-Income Countries During 2025-2026, Tripling From 2024
GSK, Pfizer And Shionogi-owned ViiV Healthcare Will Make At Least 2M Doses Of Long-Acting Cabotegravir For HIV Pre-exposure Prophylaxis Available For Procurement For Low- And Middle-Income Countries During 2025-2026, Tripling From 2024
高盛、輝瑞和神岡持有的ViiV Healthcare將在2025-2026年至少製造200萬劑長效卡博替格韋用於HIV預防接觸，並提供給低收入和中等收入國家採購，較2024年增加三倍
GSK, Pfizer And Shionogi-owned ViiV Healthcare Will Make At Least 2M Doses Of Long-Acting Cabotegravir For HIV Pre-exposure Prophylaxis Available For Procurement For Low- And Middle-Income Countries During 2025-2026, Tripling From 2024
高盛、輝瑞和神岡持有的ViiV Healthcare將在2025-2026年至少製造200萬劑長效卡博替格韋用於HIV預防接觸，並提供給低收入和中等收入國家採購，較2024年增加三倍
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。